Management Team Irach TaraporewalaChief Executive Officer and President Dr. Taraporewala has over 30 years in drug development and regulatory affairs experience. He was formerly the Vice President of Regulatory Affairs and Clinical Research at Austin, TX-based Mystic Pharmaceuticals Inc. where he led the regulatory strategy for the company’s ophthalmic and intranasal drug products and drug delivery systems. Prior to that, Dr. Taraporewala served as Senior Consultant in the Drug Development Consulting division of Boston-based PAREXEL International Corp., a leading global pharmaceutical services provider, where he provided technical expertise and regulatory advice to small and large biotechnology and pharmaceutical company clients worldwide, and also conducted due diligence for companies and venture capital firms on technology and portfolio evaluation and product acquisitions. From 1998 to 2004, Dr. Taraporewala was Director of Chemistry and Quality Control at Yonkers, NY-based Advanced Viral Research Corporation where he helped take OHR/AVR118, an immunomodulator drug, into clinical trials for AIDS, cancer cachexia and rheumatoid arthritis, working closely with Shalom Hirschman, M.D., Ohr’s Chief Scientific Advisor. Prior to that, Dr. Taraporewala worked in research and development at CIBA-Geigy, which later merged with Sandoz to become Novartis. He has also served as principal investigator on four National Institute of Health and U.S. Department of Defense funded biomedical research grants on antiviral drugs, DNA-based cancer diagnostics and on antimalarial compound development. Dr. Taraporewala earned bachelors’ and masters’ degrees in chemistry and microbiology from the University of Bombay, India and a Ph.D. in medicinal chemistry from the Philadelphia College of Pharmacy. He conducted postdoctoral research at the University of Texas at Austin, the University of Minnesota and the Southwest Foundation for Biomedical Research. Dr. Taraporewala has multiple scientific publications and patents to his credit, and has lectured extensively. Sam BackenrothChief Financial Officer and Vice President of Business Development Mr. Backenroth has executive experience in advising and financing biotechnology companies. He previously worked as an Investment Banker with The Benchmark Company LLC, an Investment Banking firm specializing in micro-cap biotechnology transactions. While at Benchmark, Sam helped fund numerous small biotechnology companies raise equity growth capital through a variety of structures. Mr. Backenroth also acted as an advisor to multiple public and private biotechnology and pharmaceutical companies in assisting with business development activities, joint ventures, licensing, strategic partnerships, and mergers & acquisitions. He graduated with honors from Touro College with a Bachelor’s degree in finance. Dr. Shalom Z. HirschmanChief Scientific Advisor Dr. Shalom Z. Hirschman has had a long career as an academic physician, research scientist, educator, and, most recently, biotechnology entrepreneur and consultant. Dr. Hirschman served as intern and resident in medicine at The Massachusetts General Hospital of the Harvard Medical School from 1961-1963. Between 1963-1969 he conducted research in molecular biology at the National Institutes of Health in Bethesda, MD. He joined the world-renowned founding faculty of The Mount Sinai School of Medicine in 1968 where he was appointed as Director of the Division of Infectious Diseases and Professor of Medicine. For several years Dr. Hirschman also served as vice-chairman of the Department of Medicine. He retired from Mount Sinai in 1997 and joined Advanced Viral Research Corp. as its chief executive officer, president, and chief scientific officer. There he successfully created a very new type of peptide-based drug, built a FDA approved manufacturing facility and brought this drug into clinical trials under INDs with the US FDA. He retired from this position at the end of 2004 and since has served as consultant to educational institutions and biotechnology investment funds. Dr. Hirschman was the founder of Xtramedics, the forerunner company of Quantrx, and serves as a member of the board. A founder of Touro College, Dr. Hirschman currently serves as Consulting Senior Vice-President for Graduate and Professional Education.